S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Lowered by Zacks Investment Research

Tuesday, February 23, 2021 | MarketBeat

Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, "Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States. "

Separately, HC Wainwright reissued a "buy" rating and issued a $21.00 target price (up from $18.00) on shares of Verrica Pharmaceuticals in a report on Thursday, December 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of "Hold" and an average price target of $14.35.

VRCA stock opened at $14.69 on Tuesday. The firm has a fifty day moving average price of $12.78 and a 200 day moving average price of $9.90. Verrica Pharmaceuticals has a fifty-two week low of $6.02 and a fifty-two week high of $16.91. The firm has a market cap of $379.97 million, a PE ratio of -11.13 and a beta of 2.30.

A number of institutional investors and hedge funds have recently modified their holdings of VRCA. BNP Paribas Arbitrage SA lifted its position in shares of Verrica Pharmaceuticals by 360.6% during the third quarter. BNP Paribas Arbitrage SA now owns 3,298 shares of the company's stock worth $26,000 after purchasing an additional 2,582 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in shares of Verrica Pharmaceuticals by 37.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 672,650 shares of the company's stock worth $5,206,000 after purchasing an additional 182,956 shares during the last quarter. FinTrust Capital Advisors LLC bought a new stake in shares of Verrica Pharmaceuticals during the third quarter worth $77,000. Capital Investment Advisory Services LLC bought a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth $174,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth $199,000. Institutional investors own 33.97% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Story: How Investors Can Profit from Options Trading

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Stocks It May Be Time To Take Profits On

Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.

Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.

Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.

View the "7 Stocks It May Be Time To Take Profits On".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.